[C:1]([O:5][C:6]([CH3:9])([CH3:8])[CH3:7])(=[O:4])[NH:2][NH2:3].C(N(CC)CC)C.CO[C:19]([C:21]1[N:26]=[C:25]([C:27]2[CH:28]=[N:29][CH:30]=[C:31]([Cl:33])[CH:32]=2)[C:24]2[N:34]([CH2:44][C@H:45]3[CH2:50][CH2:49][C@H:48]([CH3:51])[CH2:47][CH2:46]3)[C:35]([N:37]3[CH2:41][CH2:40][CH2:39][C@H:38]3[CH2:42][F:43])=[N:36][C:23]=2[CH:22]=1)=[NH:20]>C(O)C.CCOC(C)=O>[Cl:33][C:31]1[CH:32]=[C:27]([C:25]2[C:24]3[N:34]([CH2:44][C@H:45]4[CH2:50][CH2:49][C@H:48]([CH3:51])[CH2:47][CH2:46]4)[C:35]([N:37]4[CH2:41][CH2:40][CH2:39][C@H:38]4[CH2:42][F:43])=[N:36][C:23]=3[CH:22]=[C:21]([C:19](=[NH:20])[NH:3][NH:2][C:1]([O:5][C:6]([CH3:9])([CH3:8])[CH3:7])=[O:4])[N:26]=2)[CH:28]=[N:29][CH:30]=1Tert-butyl carbazate (106 mg, 0.802 mmol) and triethylamine (418 μL, 3.006 mmol) were added to a solution of crude methyl-4-(5-chloropyridin-3-yl)-2-[(2S)-2-(fluoromethyl)pyrrolidin-1-yl]-3-[(trans-4-methylcyclohexyl)methyl]-3H-imidazo[4,5-c]pyridin-6-carbimidate (Example 14.2, Step 1; 50 mg, 0.100 mmol) in ethanol (100 μL) in a vial, and the reaction was capped and stirred at ambient temperature for 72 hr. The reaction was diluted with EtOAc and washed with water and brine. The organic layer was dried over Na2SO4, filtered, and concentrated to afford crude tert-butyl 2-((4-(5-chloropyridin-3-yl)-2-((S)-2-(fluoromethyl)pyrrolidin-1-yl)-3-((trans-4-methylcyclohexyl)methyl)-3H-imidazo[4,5-c]pyridin-6-yl)(imino)methyl)hydrazinecarboxylate. MS ESI calc'd. for C30H40ClFN8O2 [M+H]+ 599. found 599. This material was taken on to Step 2 without further purification.